Concepedia

James E. Butrynski

JE

Statistics

Publications

39

Citations

4.4K

H-Index

27

Active since

1992

Affiliations

Dana-Farber Cancer Institute(Current)

Brigham and Women's Hospital

Harvard University

Massachusetts General Hospital

Dana-Farber/Harvard Cancer Center

James E. Butrynski is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and radiation oncology.

Top concepts

Publications per year

1992–2024

39

Publications

39

Crizotinib in<i>ALK</i>-Rearranged Inflammatory Myofibroblastic Tumor

James E. Butrynski, David R. D’Adamo, Jason L. Hornick et al. · New England Journal of Medicine · 2010 · 851 citations

, , +9

The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers

Takaaki Sasaki, Katsuhiro Okuda, Wei Zheng et al. · Cancer Research · 2010 · 328 citations · Full text

, , +13

Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas

Suzanne George, Priscilla Merriam, Robert G. Maki et al. · Journal of Clinical Oncology · 2009 · 315 citations · Full text

, , +12

[<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Tomography Predicts Outcome for Ewing Sarcoma Family of Tumors

Douglas S. Hawkins, Scott M. Schuetze, James E. Butrynski et al. · Journal of Clinical Oncology · 2005 · 282 citations · Full text

Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial

Suzanne George, Qian Wang, Michael C. Heinrich et al. · Journal of Clinical Oncology · 2012 · 245 citations · Full text

1–5 of 39